Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00048555

Public ClinicalTrials.gov record NCT00048555. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination With Rituxan® for Patients With Relapsed or Refractory, Follicular Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® \[Rituxan® as a single agent is approved by the United States Food and Drug Administration (FDA) to treat patients with relapsed or refractory follicular NHL\], has in this patient population.

Study identification

NCT ID: NCT00048555
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Biogen; Industry
Enrollment: 90 participants

Conditions and interventions

Conditions

Non-Hodgkin's Lymphoma

Interventions

IDEC-114 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2002 (Type not available)
Primary completion: Mar 2004 (Actual)
Completion: Nov 2010 (Actual)
Last update posted: Sep 16, 2013

2002 – 2010

United States locations

U.S. sites: 22
U.S. states: 17
U.S. cities: 22

Facility	City	State	ZIP	Site status
Research site	Birmingham	Alabama	35294	—
Research site	Tucson	Arizona	85724	—
Research site	Los Angeles	California	90095	—
Research site	Newport Beach	California	92658	—
Research site	San Diego	California	92121	—
Research site	Aurora	Colorado	80010	—
Research site	Washington D.C.	District of Columbia	20007	—
Research site	Tampa Bay	Florida	33612	—
Research site	Chicago	Illinois	60611	—
Research site	Maywood	Illinois	60153	—
Research site	Boston	Massachusetts	2115	—
Research site	Detroit	Michigan	48202	—
Research site	Rochester	Minnesota	55905	—
Research site	Omaha	Nebraska	68198	—
Research site	Buffalo	New York	14263	—
Research site	New York	New York	10021	—
Research site	Rochester	New York	14642	—
Research site	Durham	North Carolina	27710	—
Research site	Philadelphia	Pennsylvania	1906	—
Research site	Columbia	South Carolina	29210	—
Research site	Houston	Texas	77030	—
Research site	Charlottesville	Virginia	22908	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00048555, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 16, 2013 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00048555 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →